Lack of pharmacokinetic interaction between the novel mGluR5 antagonist AFQ056 and levodopa/carbidopa in healthy volunteers

被引：0
|
作者：
Chakraborty, A.
Ufer, M.
Bhad, P.
Vandemeulebroecke, M.
Gomez-Mancilla, B.
Bell, D.
Winter, S.
Woessner, R.
机构：
来源：
MOVEMENT DISORDERS | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
456
引用
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [31] 12-week, double-blind, placebo-controlled, fixed-dose study of immediate release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias
    Stocchi, F.
    Balaguer, E.
    Trenkwalder, C.
    Shah, A.
    Dronamraju, N.
    Tran, M.
    Kenney, C.
    Graf, A.
    MOVEMENT DISORDERS, 2014, 29 : S268 - S268
  • [32] 13-week, double-blind, placebo-controlled, fixed-dose study of modified release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias
    Trenkwalder, C.
    Kulisevsky, J.
    Poewe, W.
    Shah, A.
    Han, G.
    Tran, M.
    Kenney, C.
    Graf, A.
    MOVEMENT DISORDERS, 2014, 29 : S271 - S272
  • [33] Lack of pharmacokinetic interaction between grapefruit juice and phenytoin in healthy male volunteers and epileptic patients
    Kumar, N
    Garg, SK
    Prabhakar, S
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (09): : 629 - 632
  • [34] Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa
    Almeida, L
    Vaz-da-Silva, M
    Silveira, P
    Falcao, A
    Maia, J
    Loureiro, A
    Torrao, L
    Machado, R
    Wright, L
    Soares-da-Silva, P
    CLINICAL NEUROPHARMACOLOGY, 2004, 27 (01) : 17 - 24
  • [35] Lack of interaction between pizotifen and the novel antimigraine compound zolmitriptan in healthy volunteers
    Seaber, EJ
    Gillotin, C
    Mohanlal, R
    Layton, G
    Posner, J
    Peck, R
    CLINICAL DRUG INVESTIGATION, 1997, 14 (03) : 221 - 225
  • [36] Lack of Interaction Between Pizotifen and the Novel Antimigraine Compound Zolmitriptan in Healthy Volunteers
    Emma J. Seaber
    C. Gillotin
    R. Mohanlal
    G. Layton
    J. Posner
    R. Peck
    Clinical Drug Investigation, 1997, 14 : 221 - 225
  • [37] Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers
    Chen, LC
    Chou, MH
    Lin, MF
    Yang, LL
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (06) : 453 - 459
  • [38] Lack of interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers
    Veronese, L
    Gillotin, C
    MarionGallois, R
    Weatherley, BC
    Thebault, JJ
    Guillaume, M
    Peck, RW
    CLINICAL DRUG INVESTIGATION, 1997, 14 (03) : 217 - 220
  • [39] Lack of Interaction Between Oral Dihydroergotamine and the Novel Antimigraine Compound Zolmitriptan in Healthy Volunteers
    L. Veronese
    C. Gillotin
    R. Marion-Gallois
    B. C. Weatherley
    J. J. Thebault
    M. Guillaume
    Richard W. Peck
    Clinical Drug Investigation, 1997, 14 : 217 - 220
  • [40] Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers:: An open-label, randomized, crossover, pharmacokinetic interaction clinical trial
    Portoles, A.
    Calvo, A.
    Terleira, A.
    Laredo, L.
    Resplandy, G.
    Gorostiaga, G.
    Moreno, A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10): : 1195 - 1203
12345